Product Description
Mechanisms of Action: Calcium Channel Blocker
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: Argentina | Bangladesh | Belgium | Bulgaria | Chile | Colombia | Croatia | Cyprus | Czech | Dominican Republic | Ecuador | Egypt | Greece | Hong Kong | Hungary | India | Indonesia | Israel | Italy | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malta | Mexico | Pakistan | Peru | Philippines | Portugal | Romania | Russia | Saudi Arabia | Spain | Taiwan | Tunisia | Turkey | Ukraine | United Arab Emirates | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: Menarini
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 4: Spasm|Irritable Bowel Syndrome|Abdominal Pain
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
ACTRN12620000773932p |
CUH_2009_VPA | N/A |
Not yet recruiting |
Other |
None |
|||
2017-003258-18 |
The DOMINO trial: Diet Or Medication in Irritable bowel syNdrOme | P4 |
Completed |
Irritable Bowel Syndrome|Spasm|Abdominal Pain |
2019-11-14 |
2022-03-13 |
Treatments |
|
NCT02576340 |
Randomized Prospective Trial | P4 |
Completed |
Spasm |
2013-05-01 |
2021-07-09 |
Primary Endpoints|Treatments |
|
2005-001655-38 |
2005-001655-38 | P4 |
Completed |
Irritable Bowel Syndrome |
2007-03-06 |
2022-03-12 |
Treatments |
